G
52.76
0.13 (0.25%)
| Previous Close | 52.63 |
| Open | 50.61 |
| Volume | 1,015,230 |
| Avg. Volume (3M) | 1,252,546 |
| Market Cap | 2,127,882,496 |
| Price / Sales | 12.44 |
| Price / Book | 0.780 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Operating Margin (TTM) | -482.59% |
| Diluted EPS (TTM) | -59.59 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 9.70 |
| Operating Cash Flow (TTM) | -464.88 M |
| Levered Free Cash Flow (TTM) | -236.88 M |
| Return on Assets (TTM) | -11.98% |
| Return on Equity (TTM) | -62.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | GRAIL, Inc. | Bearish | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.0 |
| Insider Activity | -4.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 66.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 130.00 (Guggenheim, 146.40%) | Buy |
| Median | 81.00 (53.53%) | |
| Low | 60.00 (Morgan Stanley, 13.72%) | Hold |
| Average | 88.00 (66.79%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 64.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 24 Feb 2026 | 60.00 (13.72%) | Hold | 50.35 |
| Baird | 20 Feb 2026 | 82.00 (55.42%) | Buy | 50.21 |
| 17 Feb 2026 | 113.00 (114.18%) | Buy | 99.03 | |
| Canaccord Genuity | 20 Feb 2026 | 80.00 (51.63%) | Buy | 50.21 |
| Guggenheim | 26 Jan 2026 | 130.00 (146.40%) | Buy | 106.31 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FREIDIN AARON | - | 49.82 | -2,492 | -124,151 |
| OFMAN JOSHUA J. | - | 49.82 | -2,937 | -146,321 |
| RAGUSA ROBERT P | - | 49.82 | -7,461 | -371,707 |
| Aggregate Net Quantity | -12,890 | |||
| Aggregate Net Value ($) | -642,180 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 49.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RAGUSA ROBERT P | Officer | 09 Mar 2026 | Sell (-) | 7,461 | 49.82 | 371,707 |
| OFMAN JOSHUA J. | Officer | 09 Mar 2026 | Sell (-) | 2,937 | 49.82 | 146,321 |
| FREIDIN AARON | Officer | 09 Mar 2026 | Sell (-) | 2,492 | 49.82 | 124,151 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |